FDA Warns Danish Drugmaker for Testing Failures
The FDA issued a warning letter to DermaPharm for serious GMP violations including inadequate testing of raw materials and finished products.
Source: Devices & Diagnostics Letter
The FDA issued a warning letter to DermaPharm for serious GMP violations including inadequate testing of raw materials and finished products.
Source: Devices & Diagnostics Letter